Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Trial details
- Registry ID
- NCT07404865
- Drugs studied
- Telitacicept
TrialRedline tracks 3 clinical trials sponsored by Vor Biopharma: 3 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseNCT07404865 | Telitacicept | Recruiting | 2028-12Estimated |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)NCT06456580 | Telitacicept | Active not recruiting | 2027-03Estimated |
| A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)NCT05306574 | Telitacicept | Terminated | 2025-01-06Actual |
Names as written in the registry records.
NCT06456580 · Vor Biopharma
Before: Estimated. After: Actual.
Before: 180 participants (planned). After: 191 participants (actual).
Before: May 2027. After: Mar 2027.
Before: Recruiting. After: Active not recruiting.
NCT07404865 · Vor Biopharma
Before: Jun 2028. After: Dec 2028.
NCT07404865 · Vor Biopharma
Before: Not yet recruiting. After: Recruiting.
NCT06456580 · Vor Biopharma
Before: Dec 2026. After: May 2027.
NCT06456580 · Vor Biopharma
Before: Jul 2026. After: Dec 2026.
Before: Estimated. After: Actual.
Before: 350 participants (planned). After: 91 participants (actual).
Before: Estimated. After: Actual.
Before: 2 Jan 2027. After: 6 Jan 2025.
Before: Active not recruiting. After: Terminated.